Equity Profile

COGT

Cogent Biosciences, Inc.

Health CareBiotechnology$6.0B

May5Tue

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing therapies for genetically defined diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

$-0.54

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q1-2026 Earnings Preview

Context

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing therapies for genetically defined diseases. With a market cap of $6 billion, it operates in the healthcare sector, which is increasingly important as innovation in drug development continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In the last quarter, Cogent reported an EPS of $-0.64, missing estimates by 17%. The stock reacted with a slight decline of 0.19% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Cogent to report a loss this quarter, with a consensus EPS of $-0.54. Investors will be looking for any signs of improved performance or future revenue potential.

Bull Case

If the company can demonstrate progress in its drug development pipeline or provide positive updates on upcoming therapies, it could lead to a more optimistic outlook and a potential stock rally.

Bear Case

Conversely, if the company continues to miss earnings expectations or fails to provide any promising updates, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$-0.54

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide any updates on its drug development pipeline?

Investors will closely watch for any signs of progress or setbacks that could impact future revenue potential.

How does management plan to address the ongoing losses?

Understanding the company's strategy for managing costs and improving profitability will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for positive updates on drug development, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The options market is pricing a 10.34% move, indicating higher volatility expectations than historical averages.

Recent earnings history shows that even with misses, the stock has often rebounded the following day.

Key Risk

If the company can provide any positive news regarding its pipeline, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in determining whether the company can stabilize its financials and regain investor confidence.

Bull Confirmed If

A narrower EPS loss of $-0.46 or better could signal improved operational efficiency.

Bear Confirmed If

An EPS loss greater than $-0.66 would confirm ongoing challenges in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±10.34%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move around the earnings report, indicating uncertainty among investors.

Options price a 10.34% move but the stock has averaged only 3.6% over the last 8 quarters — setup is rich.

Detail

30d HV

51.9%

Calls (42K)P/C Ratio: 0.06Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations with an EPS of $-0.46 or better, history suggests a potential stock increase of around +2.45%.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

A miss on EPS, particularly if it exceeds $-0.66, could lead to a decline, with history suggesting an average drop of around +3.44%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of drug candidates in development.
2Any commentary on cost management strategies.
3Insights into future revenue expectations.
4Management's outlook on market conditions affecting the biotech sector.
5Responses to analyst questions regarding operational challenges.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing therapies for genetically defined diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

$-0.54

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In the last quarter, Cogent reported an EPS of $-0.64, missing estimates by 17%. The stock reacted with a slight decline of 0.19% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Cogent to report a loss this quarter, with a consensus EPS of $-0.54. Investors will be looking for any signs of improved performance or future revenue potential.

Bull Case

If the company can demonstrate progress in its drug development pipeline or provide positive updates on upcoming therapies, it could lead to a more optimistic outlook and a potential stock rally.

Bear Case

Conversely, if the company continues to miss earnings expectations or fails to provide any promising updates, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$-0.54

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide any updates on its drug development pipeline?

Investors will closely watch for any signs of progress or setbacks that could impact future revenue potential.

How does management plan to address the ongoing losses?

Understanding the company's strategy for managing costs and improving profitability will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for positive updates on drug development, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The options market is pricing a 10.34% move, indicating higher volatility expectations than historical averages.

Recent earnings history shows that even with misses, the stock has often rebounded the following day.

Key Risk

If the company can provide any positive news regarding its pipeline, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in determining whether the company can stabilize its financials and regain investor confidence.

Bull Confirmed If

A narrower EPS loss of $-0.46 or better could signal improved operational efficiency.

Bear Confirmed If

An EPS loss greater than $-0.66 would confirm ongoing challenges in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±10.34%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move around the earnings report, indicating uncertainty among investors.

Options price a 10.34% move but the stock has averaged only 3.6% over the last 8 quarters — setup is rich.

Detail

30d HV

51.9%

Calls (42K)P/C Ratio: 0.06Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations with an EPS of $-0.46 or better, history suggests a potential stock increase of around +2.45%.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

A miss on EPS, particularly if it exceeds $-0.66, could lead to a decline, with history suggesting an average drop of around +3.44%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of drug candidates in development.
2Any commentary on cost management strategies.
3Insights into future revenue expectations.
4Management's outlook on market conditions affecting the biotech sector.
5Responses to analyst questions regarding operational challenges.